IL1B and COVID-19: Also, itaconate and its derivative 4-Octyl itaconate, (4-OI), inhibits NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation, preventing the secretion of IL-1β [23] which is implicated in COVID-19 immunopathology [24].